Ivabradine Zentiva (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the primary pacemaker of the heart. Inhibition of this current slows the spontaneous depolarisation of pacemaker cells, producing a controlled reduction in heart rate without affecting contractility or blood pressure.

The specific dose of Ivabradine Zentiva is determined by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and concomitant therapies. Dosage adjustments are made according to therapeutic response and tolerability, following local prescribing guidelines.

Safety data for Ivabradine during pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Ivabradine and beta‑blockers lower heart rate, but Ivabradine acts selectively on the If channel without affecting beta‑adrenergic receptors, preserving blood pressure and contractility. Beta‑blockers have broader cardiovascular effects, including reduction of contractility and blood pressure, which may be advantageous or limiting depending on the patient’s profile.

Store Ivabradine Zentiva tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Ivabradine Zentiva is taken orally, usually with a glass of water. It is commonly prescribed to be taken twice daily, with the first dose taken at least 12 hours after the previous dose, but the exact schedule is set by the prescribing physician.

The most serious adverse events include symptomatic bradycardia, atrial fibrillation, severe hypotension, and heart block. Patients should be instructed to report any episodes of dizziness, fainting, palpitations, or visual disturbances promptly.

Ivabradine is contraindicated in patients with severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, or a resting heart rate below 60 bpm before treatment. It should also be avoided in individuals taking strong CYP3A4 inhibitors or other agents that markedly lower heart rate.